Obviousness

Based on the provided patent text for US Patent 11261151, an analysis of obviousness under 35 U.S.C. § 103 can be conducted by identifying combinations of prior art references explicitly mentioned within the patent and explaining the motivation a person having ordinary skill in the art (PHOSITA) would have to combine them. The analysis relies on the detailed descriptions within the "Definitions" and "Description" sections of US11261151 as the source for prior art information, as no external prior art documents were provided in a dedicated "Prior Art section" beyond keywords.

Prior Art References from US11261151:

The patent text itself references the following as known prior art:

1. Fauq et al., Bioorg Med Chem Lett. 2010 May 15; 20(10):3036-3038: Discloses endoxifen hydrochloride.
2. U.S. Pat. No. 9,333,190 and U.S. Publication No. 2010/0112041: Disclose endoxifen citrate salts.
3. U.S. Publication No. 2002/0127665: Describes general methods of making gluconate salts of therapeutic agents.
4. European Patent Application No. 168175: Reports the use of the McMurry reaction to prepare tamoxifen.
5. Dickschen et al. Front Pharmacol. 2012; 3: 92. PMCID: PMC3357105: Discusses cytochrome P450 (CYP) mutations causing reduced conversion of tamoxifen to endoxifen, leading to reduced tamoxifen efficacy and increased resistance to the drug.

Obviousness Combinations and Motivations:

1. Synthesis of Endoxifen via McMurry Reaction

• Claims likely rendered obvious: Processes for preparing a mixture of (E)-endoxifen and (Z)-endoxifen (compounds of Formula (III)) by coupling the compound of Formula (II) (a structurally related ketone) to propiophenone mediated by a McMurry reaction.
• Prior Art Combination:
  • Prior Art 1 (A): European Patent Application No. 168175 teaches the preparation of tamoxifen using a McMurry reaction.
  • Prior Art 2 (B): General knowledge in the art that endoxifen is a known active metabolite of tamoxifen and is structurally very similar, defined in the patent as "4-hydroxy-N-desmethyl-tamoxifen."
• Motivation to Combine: A PHOSITA would have been motivated to apply the known McMurry reaction, taught by European Patent Application No. 168175 for tamoxifen, to synthesize endoxifen. Given the close structural relationship between tamoxifen and endoxifen, and the fact that endoxifen is a metabolite of tamoxifen, it would be a logical and straightforward approach for a skilled chemist to adapt a proven synthetic route for tamoxifen to produce endoxifen, particularly starting from structurally analogous ketone precursors (such as compound of Formula II and propiophenone mentioned in the patent). The expectation would be that the McMurry coupling would successfully form the necessary carbon-carbon double bond, without requiring undue experimentation.

2. Endoxifen Gluconate Salt Compositions

• Claims likely rendered obvious: Compositions comprising an endoxifen gluconate salt, and methods of making such salts by reacting (Z)-endoxifen with D-gluconate or L-gluconate.
• Prior Art Combination:
  • Prior Art 1 (A): The knowledge that endoxifen is an active therapeutic agent for hormone-dependent disorders.
  • Prior Art 2 (B): Fauq et al. (2010) and U.S. Pat. No. 9,333,190 / US 2010/0112041 demonstrate that endoxifen can form pharmaceutically acceptable salts, specifically hydrochloride and citrate salts.
  • Prior Art 3 (C): U.S. Publication No. 2002/0127665 teaches general methods for making gluconate salts of therapeutic agents.
• Motivation to Combine: A PHOSITA, aware of the therapeutic utility of endoxifen and the existence of various pharmaceutically acceptable endoxifen salts (HCl, citrate), would be motivated to explore other pharmaceutically acceptable salts, such as gluconate salts, to potentially improve properties like solubility, stability, or patient tolerability. Gluconic acid is a commonly used pharmaceutical counterion. The general knowledge of methods for preparing gluconate salts of therapeutic agents (from U.S. Publication No. 2002/0127665) would provide the PHOSITA with a known approach and a reasonable expectation of success in forming an endoxifen gluconate salt. The patent itself notes, "Methods of making gluconate salts of therapeutic agents are known in the art (for example, U.S. Publication No. 2002/0127665)."

3. Methods of Treating Tamoxifen-Refractory or SSRI-Treated Patients with Endoxifen

• Claims likely rendered obvious: Methods of treating subjects having tamoxifen-refractory or tamoxifen-resistant hormone-dependent disorders, or subjects who are or will be treated with an SSRI drug, by administering an endoxifen composition.
• Prior Art Combination:
  • Prior Art 1 (A): The established use of tamoxifen for hormone-dependent breast and reproductive tract cancers.
  • Prior Art 2 (B): The knowledge that endoxifen is the active metabolite of tamoxifen.
  • Prior Art 3 (C): Dickschen et al. (2012) details that CYP mutations can lead to reduced conversion of tamoxifen to endoxifen, decreasing tamoxifen's efficacy and increasing resistance. The patent further explains that certain SSRIs (e.g., citalopram, escitalopram, fluoxetine, paroxetine, sertraline, and vilazodone) can inhibit the CYP2D6 enzyme, which is crucial for the conversion of N-desmethyl tamoxifen to endoxifen.
• Motivation to Combine: A PHOSITA facing the known problem of tamoxifen resistance or reduced efficacy in certain patient populations (e.g., those with CYP2D6 mutations or those concomitantly taking CYP2D6-inhibiting SSRIs) would be highly motivated to administer the active metabolite, endoxifen, directly. The patent explicitly identifies the problem: "Several cytochrome P450 (CYP) mutations have been proposed to cause reduced conversion of tamoxifen to its active metabolite, endoxifen, and reduce tamoxifen efficacy and increase resistance to the drug." Therefore, bypassing the problematic metabolic step by administering endoxifen directly to these patients would be an obvious solution to a known problem.

Areas Less Susceptible to Obviousness (Based on Limited Prior Art):

• Specific Crystalline Forms: The patent claims novel crystalline Forms I, II, and III of the compound of Formula (III), characterized by specific X-ray powder diffraction (XRPD) patterns. The provided prior art references do not disclose these specific polymorphic forms or methods that would inherently and predictably produce them. While the general goal of identifying and characterizing polymorphs for improved drug properties is known, the discovery of specific, non-obvious crystal forms with advantageous properties (e.g., improved bioavailability, stability) would typically not be rendered obvious without prior art teaching those specific forms or a clear and predictable path to their discovery.
• Specific Pharmacokinetic Profiles (if unexpected): The patent claims compositions achieving particular pharmacokinetic profiles, such as a mean half-life of endoxifen between 30 and 60 hours, a steady-state plasma level of 25-300 nM, and specific AUC values. While optimizing PK profiles is a routine endeavor in drug development, if these specific ranges represent unexpected improvements or solve a previously unrecognized problem, they might be non-obvious. However, if these profiles are merely the expected result of known formulation strategies (e.g., enteric/delayed release, as claimed in the patent), then the claims might be more susceptible to an obviousness challenge depending on the predictability of the results.

It is important to note that a full and conclusive obviousness analysis would typically require access to the complete text of all claims of US11261151 and the full content of the cited prior art documents to compare specific features and teachings in detail.